Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX000045 in Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Phase 2Recruiting
- Sponsor
- Tectonic Therapeutic
- Start
- Oct 2026
- Primary completion
- Nov 2027
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of TX000045 in pulmonary hypertension (PH), sponsored by Tectonic Therapeutic. Started Oct 2026; status: recruiting.
02
Drugs
TX000045
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07473700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473700.